PLIANT THERAPEUTICS, INC. (PLRX): debt financing — Pliant Therapeutics announces accelerated Phase 2b/3 trial for bexotegrast and upsizes debt facility to $150M

PLIANT THERAPEUTICS, INC.

BEACON-IPF trial implemented as pivotal, adaptive Phase 2b/3 design after EU and global health authority acceptance; expected to shorten late-stage development.
Phase 3 enrollment begins immediately after Phase 2b completes; sample size increased by 90 patients to support registration.
Oxford Finance debt facility upsized to $150M from $100M; initial $30M drawn, additional $70M contingent on bexotegrast milestones.
Cash and equivalents of $495.7M as of Dec 31, 2023 plus new facility expected to fund operations through 2026.
Bexotegrast is an oral dual-selective αvβ6/αvβ1 integrin inhibitor for IPF and PSC.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

PLIANT THERAPEUTICS, INC. incurred credit facility of $150.0 million with Oxford Finance LLC at (i) the greater of (a) 1-month term SOFR and (b) three and one-half percent (3.5 maturing March 1, 2029, which may be extended to March 1, 2030.

Instrument: credit facility
Principal: $150.0 million
Counterparty: Oxford Finance LLC
Rate: (i) the greater of (a) 1-month term SOFR and (b) three and one-half percent (3.5
Maturity: March 1, 2029, which may be extended to March 1, 2030
Event: incurrence

Exact text from the filing

pursuant to which, the Lenders have agreed to lend the Company, subject to the terms and conditions therein, a series of term loans up to an aggregate principal amount of $150.0 million (the “Term Loans”), of which $50.0 million is subject to the Lender’s sole discretion. Pursuant to the Agreement, the Company drew an initial Term Loan of $30.0 million on the

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PLIANT THERAPEUTICS, INC. amended Amended and Restated Loan and Security Agreement with Oxford Finance LLC and the lenders valued at $150.0 million (effective 2024-03-11).

Action: amendment
Agreement: credit facility
Counterparty: Oxford Finance LLC and the lenders
Value: $150.0 million
Effective: 2024-03-11

Exact text from the filing

On March 11, 2024 (the “Effective Date”), Pliant Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (“Agreement”) by and among the Company, the lenders from time to time party thereto (each a “Lender” and collectively, the “Lenders”) and Oxford Finance LLC, in its capacity as collateral agent (in such capacity, the “Agent”), which amends and restates, in its entirety, the Loan and Security Agreement, dated as of May 4, 2022

View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-065416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.